The effect of medroxyprogesterone acetate on angiogenesis in complex endometrial hyperplasia

Gynecologic Oncology

Volumn 72, Issue 2, 1999, Pages 193-198

  Abulafia, Ovadia ^a   Triest, William E ^b   Adcock, J Tyron ^b   Sherer, David M ^b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; MEDROXYPROGESTERONE ACETATE; PARAFFIN; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PHARMACOLOGY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; ENDOMETRIUM HYPERPLASIA; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MYOMETRIUM; NEOVASCULARIZATION (PATHOLOGY); ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

EID: 0032916036     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5106     Document Type: Article

References (28)

1. DiSaia J, Creasman WT: Endometrial hyperplasia/estrogen therapy, in Clinical Gynecologic Oncology. St Louis: Mosby Year Book, 1993, pp 126-155
2. Folkman J: How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res 46:467-473, 1986
3. Knighton DR, Silver IA, Hunt TK: Regulation of wound healing angiogenesis: effects of oxygen gradients in inspired oxygen concentration. Surgery 90:262-275, 1981
4. Folkman J: Tumor angiogenesis. Adv Cancer Res 43:175-203, 1985
5. Sidky Y, Auerbach R: Lymphocyte induced angiogenesis: quantitative and sensitive assay of graft versus host reaction. J Exp Med 141:1084-1089, 1975
6. Kaplan HS: The biology of neoplasia, in Smith CH, Thier SO (eds): Pathophysiology. Philadelphia, Saunders, 1981, pp 300-307
7. Chodak GW: Tumor angiogenesis: importance in tumor detection and growth, in Ratliff TL, Catalona WJ (eds): Urologie Oncology. Boston: Martinus Nijhoff, 1984, pp 1-13
8. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6, 1990
9. Srivastava A, Laidler P, Davies RP, Horgan K, Hughes LE: The prognostic significance of tumor vascularity in intermediate thickness (0.76-4 mm thick) skin melanoma. Am J Pathol 133:419-423, 1988
10. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991
11. Macchiarini P, Fontani G, Hardin MJ, Squartini F, Angeletti CA: Relation of neovasculature to metastases of non-small cell lung cancer. Lancet 340:145-146, 1992
12. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:401-409, 1993
13. Wiggins DL, Granai CO, Steinhoff MM, Calabresi P: Tumor angiogenesis as a prognostic factor in cervical carcinoma. Gynecol Oncol 56:353-356, 1993
14. Kirschner CV, Alanis-Amezcua JM, Martin VG, Luna N, Morgan E, Yang JJ, et al: Angiogenesis factor in endometrial carcinoma: a new prognostic indicator. Am J Obstet Gynecol 174:1882-1884, 1996
15. Abulafia O, Triest WE, Sherer DM: Angiogenesis in primary and metastatic epithelial ovarian carcinoma. Am J Obstet Gynecol 177:541-547, 1997
16. Brem SS, Gullino PM, Medina D: Angiogenesis: a marker for neoplastic transformation of mammary papillary hyperplasia. Science 195:880-882, 1977
17. Abulafia O, Triest WE, Sherer DM, Hansen CC, Ghezzi F: Angiogenesis in endometrial hyperplasia and stage I endometrial carcinoma. Obstet Gynecol 86:479-485, 1995
18. Gross J, Azizkhan RG, Biwas C, Bruns RR, Hsieh DST, Folkman J: Inhibition of tumor growth, vascularization, and collangenolysis in the rabbit cornea by medroxyprogesterone. Proc Natl Acad Sci USA 78: 1176-1180, 1981
19. Oikawa T, Hiragun A, Yoshida Y, Ashino-Fuse H, Tominaga T, Iwaguchi T: Angiogenic activity of rat mammary carcinomas induced by 7,12-dimethylbenz[a] anthracene and its inhibition by medroxyprogesterone acetate: possible involvement of antiangiogenic action of medroxyprogesterone acetate in its tumor growth inhibition. Cancer Lett 43:85-92, 1988
20. Wilks JW, Scott PS, Vrba LK, Cocuzza JM: Inhibition of angiogenesis with combination treatments of angiostatic steroids and suramin. Int J Radiat Biol 60:73-77, 1991
21. Jikihara H, Terada N, Yamamoto R, Nishikawa Y, Tanizawa O, Matsumoto K, Terakawa N: Inhibitory effect of medroxyprogesterone acetate on angiogenesis induced by human endometrial cancer. Am J Obstet Gynecol 167:207-211, 1992
22. Ashino-Fuse H, Takano Y, Oikawa T, Shimamura M, Iwaguci T: Medroxyprogesterone acetate, an anti-cancer and anti-angiogenic steroid, inhibits the plasminogen activator in bovine endothelial cells. Int J Cancer 44:859-864, 1989
23. Yamamoto T, Terada N, Nishizawa Y, Petrow V: Angiostatic activities of medroxyprogesterone acetate and its analogs. Int J Cancer 56:393-399, 1994
24. Blei F, Wilson, Mignatti P, Rifkin D: Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol 155:568-578, 1993
25. Tokida Y, Aranati Y, Morita A, Kitagawa Y: Production of two variant laminin forms by endothelial cells and shift of their relative levels by angiostatic steroids. J Biol Chem 265:18123-18129, 1990
26. Fugimoto J, Fujita H, Hosoda S, Okada H, Tanaka NG: Effect of medroxyprogesterone acetate on secondary spreading of cancer. Invasion Metastasis 9:209-215, 1989
27. Mietinnen M, Lindenmyer AE, Chaubal A: Endothelial cell marker CD31, CD34, BNH9 antibody to H- and Y-antigen: evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod Pathol 7:82-90, 1994
28. Morales DE, McGowan KA, Grant DS, Masheshwari S, Bhartiya D, Cid MC, Kleiman HK, Schnaper HW: Estrogen promotes angiogenesis activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation 91:755-763, 1995